Savara introduces apap clearpath™, a gm-csf autoantibody blood test to detect autoimmune pulmonary alveolar proteinosis (apap)

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched apap clearpath™, a new serum-based blood test that can be used by physicians in the u.s. to obtain a definitive diagnosis of apap, a rare autoimmune lung disease mediated by autoantibodies targeting gm-csf. autoimmune pap accounts for approximately 90% of all patients with pap and has an estimated diagnosed prevalence of se.
SVRA Ratings Summary
SVRA Quant Ranking